Abstract
4'-Deoxydoxorubicin was given to 15 patients with drug-resistant pediatric malignant solid tumors with the objectives of determining the maximum tolerated dosage and dose-limiting toxicity. Maximum tolerated dosage was 36 mg/m2 given IV once every 3 weeks. Dose limiting toxicity was myelosuppression, which was severe and prolonged. Therapeutic benefits were not observed for these patients.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Child
-
Child, Preschool
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Doxorubicin / analogs & derivatives*
-
Doxorubicin / therapeutic use
-
Drug Evaluation
-
Female
-
Hematologic Diseases / chemically induced
-
Humans
-
Male
-
Neoplasms / drug therapy*
Substances
-
Antineoplastic Agents
-
Doxorubicin
-
esorubicin